Chiesi Farmaceutici S.p.A.

25 trials 4 recruiting Commercial sponsor

Filter these 25 trials by condition, phase, country and more.

Open in Search →

25 Registered trials

4 Recruiting

19 Completed trials

21 Countries active

12 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I (Other)

Phase III: 7 Phase II/III: 1 Phase II: 4 Phase IV: 2 Phase I: 1 Phase I (Other): 10

Oversight events:

1 temporary halt across 1 trial

View oversight register →

100%

19 of 19 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Asthma 7 Chronic obstructive pulmonary disease 3 Idiopathic pulmonary fibrosis 2 Fabry´s disease 2 Partial lipodystrophy 2 Hypoxic ischaemic encephalopathy neonatal 1

Top IMPs

GLYCOPYRRONIUM BROMIDE, FORMOTEROL FUMARATE DIHYDRATE, BECLOMETASONE DIPROPIONATE ANHYDROUS 4 TANIMILAST 4 BECLOMETASONE DIPROPIONATE, GLYCOPYRRONIUM BROMIDE, FORMOTEROL FUMARATE DIHYDRATE 2 FORMOTEROL FUMARATE DIHYDRATE, BECLOMETASONE DIPROPIONATE ANHYDROUS 2 METRELEPTIN 2 PEGUNIGALSIDASE ALFA 2 BECLOMETASONE DIPROPIONATE 1 FLUTICASONE PROPIONATE, SALMETEROL 1 PLACEBO 1 ROFLUMILAST 1 ZAMPILIMAB 1

All trials — page 2

25 total

Safety and Efficacy study assessing Pegunigalsidase Alfa (PRX-102) Administered by Intravenous Infusion Every 4 Weeks in Patients With Fabry… Ended

2024-516735-27-00 Phase III 5 countries PEGUNIGALSIDASE ALFA

Showing 25–25 of 25 trials

← All sponsors A–Z